Publications by authors named "Steven Reich"

Claim this Profile
M
Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data.
Daniela A Bota, Warren Mason, Santosh Kesari, Rajiv Magge, Benjamin Winograd, Steven D Reich

Neurooncol Adv· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multidisciplinary care considerations for gender nonconforming adolescents with eating disorders: A case series.
Abigail A Donaldson, Allison Hall, Jodie Neukirch, Vania Kasper, Shannon Simones, Steven Reich

Int J Eat Disord· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.
Andrew Spencer, Simon Harrison, Jeffrey Zonder, Ashraf Badros, Jacob Laubach, Steven D Reich

Br J Haematol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors.
Geoffrey I Shapiro, Ulka N Vaishampayan, Patricia LoRusso, Jeremy Barton, Steven Hua, Steven D Reich

Invest New Drugs· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.
Simon J Harrison, Paul Mainwaring, Timothy Price, Michael J Millward, Peeter Padrik, Steven D Reich

Clin Cancer Res· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.
Nancy Levin, Andrew Spencer, Simon J Harrison, Dharminder Chauhan, Francis J Burrows, Steven D Reich

Br J Haematol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating imbalances of adverse events during biosimilar development.
Alicia M Vana, Amy W Freyman, Steven D Reich, Donghua Yin, Ruifeng Li

MAbs· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.
Paul G Richardson, Todd M Zimmerman, Craig C Hofmeister, Moshe Talpaz, Asher A Chanan-Khan, Steven Reich

Blood· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case of myelopathy because of enchondromas from Maffucci syndrome with successful surgical treatment.
Christopher M McCarthy, Haim Blecher, Steven Reich

Spine J· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01).
Donghua Yin, Kerry B Barker, Ruifeng Li, Xu Meng, Steven D Reich

Br J Clin Pharmacol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Splenic artery embolization: a single center experience on the safety, efficacy, and clinical outcomes.
Ron C Gaba, Jeremy R Katz, Ahmad Parvinian, Steven Reich, Benedictta O Omene

Diagn Interv Radiol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of short term synaptic depression and stochastic vesicle dynamics on neuronal variability.
Steven Reich, Robert Rosenbaum

J Comput Neurosci· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lumbar hemangioma masking a plasma cell tumor--case report and review of the literature.
Maahir U Haque, Adam N Wilson, Haim D Blecher, Steven M Reich

Spine J· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer.
Jianqing Lin, Marianna Zahurak, Tomasz M Beer, Charles J Ryan, George Wilding, Steven D Reich

Urol Oncol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas.
Monica M Mita, Matthew A Spear, Lorrin K Yee, Alain C Mita, Elisabeth I Heath, Steven D Reich

Clin Cancer Res· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors.
Sarah A Lowndes, Avril Adams, Anthony Timms, Nita Fisher, Jon Smythe, Steven Reich

Clin Cancer Res· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of an association between Chlamydia psittaci and ocular adnexal lymphoma.
Grace S Zhang, Jane N Winter, Daina Variakojis, Steven Reich, Gary S Lissner

Leuk Lymphoma· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Francis J Giles, William T Bellamy, Zeev Estrov, Susan M O'Brien, Srdan Verstovsek, Steven D Reich

Leuk Res· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.
Hope S Rugo, Roy S Herbst, Glenn Liu, John W Park, Merrill S Kies, Steven D Reich

J Clin Oncol· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.
Glenn Liu, Hope S Rugo, George Wilding, Teresa M McShane, Jeffrey L Evelhoch, Steven D Reich

J Clin Oncol· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial.
Peter Heald, Marilyn Mehlmauer, Ann G Martin, Constance A Crowley, Richard C Yocum, Steven D Reich

J Am Acad Dermatol· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis